Tirzepatide is a synthetic research peptide functioning as a dual agonist of the GIP and GLP-1 receptors, two incretin pathways widely studied for their roles in metabolic regulation.
It is frequently explored in research related to insulin signaling, glucagon modulation, energy balance, and gastrointestinal physiology. Its dual-pathway mechanism makes it a relevant compound in metabolic and endocrine studies.
This compound is provided as a lyophilized powder.
Couldn't load pickup availability
Alias / Product Clarification
GLP-2TZ – 10mg = Tirzepatide 10mg
For research use only. Not for human consumption.
Need reconstitution solution? Don't forget to add Bacteriostatic Water — available as a quick add in your cart before checkout.
Dual-Action Research Peptide
Two Receptors, One Molecule: The Science of Dual Activation
Tirzepatide represents a novel approach in incretin-based peptide research. Unlike single-target compounds, it activates two key receptors simultaneously: GLP-1 and GIP. This dual-agonist mechanism has been extensively documented in peer-reviewed literature for its interaction with metabolic pathways including glucose homeostasis and incretin signaling mechanisms.
- Activates both GLP-1 and GIP receptors simultaneously
- First compound designed with this dual-agonist mechanism
- Extended half-life suitable for weekly research protocols
- Well-documented in peer-reviewed scientific journals
- Stable compound suitable for in-vitro research protocols
For laboratory and in-vitro research use only. Not for human or animal use.
Molecular Design
Why Two Receptors Work Better Than One
Tirzepatide was not designed to activate both receptors equally. It binds with high affinity to GIP receptors (comparable to endogenous GIP) but exhibits lower affinity for GLP-1 receptors (approximately 5-fold less than native GLP-1). This differential binding profile is intentional. Published research indicates this combination creates a synergistic effect, where the combined receptor activation produces distinct outcomes compared to single-receptor agonism.
- High binding affinity to GIP receptors (comparable to endogenous hormone)
- Lower binding affinity to GLP-1 receptors (~5× less than native GLP-1)
- Differential binding creates synergy between both pathways
- Combined receptor activation distinct from mono-agonism
- Novel tool for dual-receptor pharmacology research
For laboratory and in-vitro research use only. Not for human or animal use.
Research Applications
Areas of Scientific Investigation
Tirzepatide has become a valuable tool for researchers exploring dual-receptor agonism and incretin pathway interactions. Because it affects two signaling pathways simultaneously, it enables investigation of receptor cross-talk and synergistic mechanisms that were difficult to study with single-target compounds. The scientific literature continues to expand with new findings.
- GLP-1 and GIP receptor binding kinetics
- Dual agonist mechanisms in cell-based assays
- Incretin pathway signaling studies
- Hepatic receptor interaction research
- Cardiovascular biomarker correlation studies
- Comparative analysis of mono vs dual receptor activation
For laboratory and in-vitro research use only. Not for human or animal use.
Understanding Tirzepatide: Mechanism of Action
Tirzepatide represents a novel approach in incretin-based research. Most peptides in this category target a single receptor — such as GLP-1 agonists like semaglutide. Tirzepatide is structurally distinct: it is the first compound designed to activate both GLP-1 and GIP receptors simultaneously. This dual-agonist mechanism is why researchers find it valuable for studying receptor cross-talk and metabolic pathway interactions.
The molecule demonstrates differential receptor affinity. It binds to GIP receptors with high affinity (comparable to endogenous GIP), while exhibiting approximately 5-fold lower affinity for GLP-1 receptors compared to native GLP-1. Published research indicates this "imbalanced" binding profile contributes to its unique pharmacological characteristics.
When both receptor pathways are engaged in this specific manner, studies have documented what researchers describe as a synergistic effect — where the combined receptor activation produces measurable outcomes distinct from single-receptor activation alone.
The compound demonstrates extended stability with a prolonged half-life, making it suitable for weekly intervals in research protocols. For scientists investigating incretin biology, receptor pharmacology, or dual-agonist mechanisms, tirzepatide offers a unique research tool for exploring how these interconnected signaling systems function.
For laboratory and in-vitro research use only. Not for human or animal use.
Scientific Literature
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist. Lancet. 2018;392(10160):2180-2193.
- Gallwitz B. GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes and obesity. Front Endocrinol. 2022;13:1004044.
- Farzam K, Patel P. Tirzepatide. StatPearls Publishing; 2024.
- Efficacy and safety of once-weekly tirzepatide: Systematic review and meta-analysis. Endocrine. 2024.
All our packages are shipped safely and securely with full protection.
We’re a passionate team obsessed with quality, not margins.
- Company
- Price
- Purity
- Quantity
- Shipping
-
Tirzepatide – 10mg
-
Prime Lab PeptidesPeptide Sciences
-
$80.00$200.00
- ≥99.874%99.1%
- 10mg10mg
- Free 2-Day Shipping3-10 Business Day
-
